First Bank & Trust increased its position in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 1.6% during the second quarter, according to its most recent filing with the SEC. The fund owned 3,211 shares of the medical research company’s stock after buying an additional 52 shares during the period. First Bank & Trust’s holdings in PRA Health Sciences were worth $241,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in PRA Health Sciences by 43,947.8% in the first quarter. BlackRock Inc. now owns 2,857,381 shares of the medical research company’s stock worth $186,387,000 after buying an additional 2,850,894 shares during the period. MARSHALL WACE ASIA Ltd bought a new position in PRA Health Sciences during the first quarter worth about $82,935,000. Marshall Wace North America L.P. bought a new position in PRA Health Sciences during the first quarter worth about $82,935,000. Harbour Capital Advisors LLC bought a new position in PRA Health Sciences during the second quarter worth about $6,400,000. Finally, Wells Fargo & Company MN boosted its position in PRA Health Sciences by 321.6% in the first quarter. Wells Fargo & Company MN now owns 609,515 shares of the medical research company’s stock worth $39,760,000 after buying an additional 464,931 shares during the period.

PRA Health Sciences, Inc. (NASDAQ PRAH) opened at 74.08 on Monday. The firm’s 50 day moving average is $75.01 and its 200 day moving average is $66.37. The company has a market cap of $4.63 billion, a PE ratio of 44.25 and a beta of 0.45. PRA Health Sciences, Inc. has a 52-week low of $46.52 and a 52-week high of $79.98.

COPYRIGHT VIOLATION NOTICE: “PRA Health Sciences, Inc. (NASDAQ:PRAH) Shares Bought by First Bank & Trust” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/pra-health-sciences-inc-nasdaqprah-shares-bought-by-first-bank-trust.html.

A number of equities analysts have recently issued reports on PRAH shares. Citigroup Inc. reissued a “buy” rating and set a $90.00 price objective (up previously from $73.00) on shares of PRA Health Sciences in a research report on Wednesday, June 28th. Jefferies Group LLC increased their price objective on shares of PRA Health Sciences from $72.00 to $72.50 and gave the stock a “buy” rating in a research report on Friday, April 28th. Credit Suisse Group reissued an “outperform” rating and set a $76.00 price objective (up previously from $69.00) on shares of PRA Health Sciences in a research report on Tuesday, June 6th. Bank of America Corporation started coverage on shares of PRA Health Sciences in a research report on Monday, June 26th. They issued a “buy” rating and a $89.00 price target on the stock. Finally, BidaskClub cut shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. PRA Health Sciences has a consensus rating of “Buy” and an average target price of $73.00.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.